Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program

Autolus Therapeutics showed up at the virtual ESMO conference just a few months ago with plenty of good things to say about AUTO3, its dual-targeting CAR-T for diffuse large B cell lymphoma. The safety data looked intact, and the therapy promised to be more durable than the first-generation options.